In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation (vol 123, pg 85, 2017)

被引：1
|
作者：
Sager, Jennifer E. [1 ]
Tripathy, Sasmita [1 ]
Price, Lauren S. L. [1 ]
Nath, Abhinav [2 ]
Chang, Justine [3 ]
Stephenson-Famy, Alyssa [3 ]
Isoherranen, Nina [1 ]
机构：
[1] Univ Washington, Sch Pharm, Dept Pharmaceut, Seattle, WA 98195 USA
[2] Univ Washington, Sch Pharm, Dept Med Chem, Seattle, WA 98195 USA
[3] Univ Washington, Sch Med, Dept Obstet & Gynecol, Seattle, WA 98195 USA
来源：
BIOCHEMICAL PHARMACOLOGY | 2021年 / 183卷
关键词：
D O I：
10.1016/j.bcp.2020.114306
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] The impact of CYP2D6 mediated drug-drug interaction: a systematic review on a combination of metoprolol and paroxetine/fluoxetine
    Bahar, Muh. Akbar
    Kamp, Jasper
    Borgsteede, Sander D.
    Hak, Eelko
    Wilffert, Bob
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2018, 84 (12) : 2704 - 2715
  • [32] Fluoxetine- and Norfluoxetine-Mediated Complex Drug-Drug Interactions: In Vitro to In Vivo Correlation of Effects on CYP2D6, CYP2C19, and CYP3A4
    Sager, J. E.
    Lutz, J. D.
    Foti, R. S.
    Davis, C.
    Kunze, K. L.
    Isoherranen, N.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (06) : 653 - 662
  • [33] CYP2D6 genotyping in patients on psychoactive drug therapy
    Topic, E
    Stefanovic, M
    Ivanisevic, AM
    Blazinic, F
    Culav, J
    Skocilic, Z
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2000, 38 (09) : 921 - 927
  • [34] CYP2D6 and tamoxifen: pharmacogenetic reinvention of an established drug?
    von Ahsen, Nicolas
    Binder, Claudia
    Brockmoeller, Juergen
    Oellerich, Michael
    LABORATORIUMSMEDIZIN-JOURNAL OF LABORATORY MEDICINE, 2009, 33 (05): : 293 - 302
  • [35] CYP2D6 genotype and adverse drug reaction in the ICU
    Stamer, UM
    Bayerer, B
    Hoeft, A
    Stüber, F
    INTENSIVE CARE MEDICINE, 2003, 29 : S13 - S13
  • [36] Effects of CYP2D6 Genetic Polymorphism and Drug Interaction on the Metabolism of Dacomitinib
    Han, Mingming
    Zhang, Xiaodan
    Ye, Zhize
    Wang, Jing
    Kong, Qihui
    Hu, Xiaoqin
    Qian, Jianchang
    Cai, Jianping
    Hu, Guoxin
    CHEMICAL RESEARCH IN TOXICOLOGY, 2022, 35 (02) : 265 - 274
  • [37] An evaluation of the CYP2D6 and CYP3A4 inhibition potential of metoprolol metabolites and their contribution to drug-drug and drug-herb interaction by LC-ESI/MS/MS
    Borkar, Roshan M.
    Bhandi, Murali Mohan
    Dubey, Ajay P.
    Reddy, V. Ganga
    Komirishetty, Prashanth
    Nandekar, Prajwal P.
    Sangamwar, Abhay T.
    Kamal, Ahmed
    Banerjee, Sanjay K.
    Srinivas, R.
    BIOMEDICAL CHROMATOGRAPHY, 2016, 30 (10) : 1556 - 1572
  • [38] Dose-Dependent Inhibition of CYP2D6 by Bupropion in Patients With Depression
    Hole, Kristine
    Arnestad, Marianne
    Molden, Espen
    Haslemo, Tore
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2021, 41 (03) : 281 - 285
  • [39] Hydroxychloroquine is metabolized by CYP2D6, CYP3A4 and CYP2C8, and inhibits CYP2D6, while its metabolites also inhibit CYP3A4 in vitro
    Paludetto, M.
    Kurkela, M.
    Kahma, H.
    Backman, J.
    Niemi, M.
    Filppula, A.
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2022, 78 (SUPPL 1) : S78 - S78
  • [40] Desipramine, substrate for CYP2D6 activity: population pharmacokinetic model and design elements of drug-drug interaction trials
    Gueorguieva, Ivelina
    Jackson, Kimberley
    Wrighton, Steven A.
    Sinha, Vikram P.
    Chien, Jenny Y.
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 70 (04) : 523 - 536
12345